# Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma

> **NCT06705725** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Carbiogene Therapeutics Co. Ltd.** · enrollment: 38 (estimated)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CBG002 CAR-T Cell Suspension

## Key facts

- **NCT ID:** NCT06705725
- **Lead sponsor:** Carbiogene Therapeutics Co. Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-12-26
- **Primary completion:** 2027-10-25
- **Final completion:** 2028-02-22
- **Target enrollment:** 38 (ESTIMATED)
- **Last updated:** 2024-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06705725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06705725, "Phase I Clinical Study of CBG002 CAR-T Cell in Treatment of Relapsed/refractory Multiple Myeloma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06705725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*